2020
Danon disease is an underdiagnosed cause of advanced heart failure in young female patients: a LAMP2 flow cytometric study
GURKA, Jiri, Lenka PIHEROVA, Filip MAJER, Anna CHALOUPKA, Daniela ŽÁKOVÁ et. al.Základní údaje
Originální název
Danon disease is an underdiagnosed cause of advanced heart failure in young female patients: a LAMP2 flow cytometric study
Autoři
GURKA, Jiri (203 Česká republika), Lenka PIHEROVA (203 Česká republika), Filip MAJER (203 Česká republika), Anna CHALOUPKA (203 Česká republika, domácí), Daniela ŽÁKOVÁ (203 Česká republika), Ondrej PELAK (203 Česká republika), Alice KREBSOVA (203 Česká republika), Petr PEICHL (203 Česká republika), Jan KREJČÍ (203 Česká republika, domácí), Tomáš FREIBERGER (203 Česká republika), Vojtech MELENOVSKY (203 Česká republika), Josef KAUTZNER (203 Česká republika), Tomas KALINA (203 Česká republika), Jakub SIKORA (203 Česká republika) a Milos KUBANEK (203 Česká republika, garant)
Vydání
ESC Heart Failure, San Francisco, Wiley Periodicals, 2020, 2055-5822
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 4.411
Kód RIV
RIV/00216224:14110/20:00116651
Organizační jednotka
Lékařská fakulta
UT WoS
000573314800056
Klíčová slova anglicky
Advanced heart failure; Danon disease; Lysosomal-associated membrane protein type 2; Screening; White blood cells
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 10. 10. 2021 10:21, Mgr. Tereza Miškechová
Anotace
V originále
Aims Danon disease (DD) is a rare X-linked disorder caused by mutations in the lysosomal-associated membrane protein type 2 gene (LAMP2). DD is difficult to distinguish from other causes of dilated or hypertrophic cardiomyopathy (HCM) in female patients. As DD female patients regularly progress into advanced heart failure (AHF) aged 20-40 years, their early identification is critical to improve patient survival and facilitate genetic counselling. In this study, we evaluated the prevalence of DD among female patients with non-ischemic cardiomyopathy, who reached AHF and were younger than 40 years. Methods and results The study cohort comprised 60 female patients: 47 (78%) heart transplant recipients, 2 (3%) patients treated with ventricular assist device, and 11 (18%) patients undergoing pre-transplant assessment. Aetiology of the cardiomyopathy was known in 15 patients (including two DD patients). LAMP2 expression in peripheral white blood cells (WBC) was tested by flow cytometry (FC) in the remaining 45 female patients. Whole exome sequencing was used as an alternative independent testing method to FC. Five additional female DD patients (two with different novelLAMP2mutations) were identified by FC. The total prevalence of DD in this cohort was 12%. HCM phenotype (57% vs. 9%,*P = 0.022) and delta waves identified by electrocardiography (43% vs. 0%,*P = 0.002) were significantly more frequent in DD female patients. Conclusions Danon disease is an underdiagnosed cause of AHF in young female patients. LAMP2 expression testing in peripheral WBCs by FC can be used as an effective screening/diagnostic tool to identify DD in this patient population.